1 Incidence, impact and preventative strategies for non- access site bleeding in the PCI patient Martial Hamon. MD. FESC University Hospital. Caen. France.

Slides:



Advertisements
Similar presentations
Impact of Anemia on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Steven.
Advertisements

Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48 Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin.
Predictors of Major Vascular Access Site Complications in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Insights.
Safety and Effectiveness of Bivalirudin in NSTE ACS by duration of the upstream infusion in the ACUITY trial: Implications for ED and upstream management.
Martial Hamon 1, Steven Marso 2, Sunil Rao 3, Marco Valgimigli 4, Freek Verheugt 5, Anthony Gershlick 6, Yamei Wang 8, Gabriel Steg 7, Efthymios Deliargyris.
Major Bleeding Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian,
Bivalirudin with Provisional GPIIb/IIIa Inhibition – the Data are Clear! Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation.
Pharmacological strategies to reduce periprocedural bleeding
Hamon M 1, Nienaber C 2, Galli S 3, Huber K 4, Gulba D 5, Hill J 6, Lafont A 7, Cequier A 8, Bernstein D 9, Deliargyris E 9 Institutions: 1. Centre Hospitalier.
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
BLEEDING AND ACUTE CORONARY SYNDROMES Cardiac Catherization Conference Syed Raza MD Cardiology Fellow VCU Medical Center 06/02/2011.
OASIS 5 Access AHA 2006 Martial Hamon, Shamir Mehta, Gabriel Steg, David Faxon, Prafulla Kerkar, Hans-Jürgen Rupprecht, Jean-Francois Tanguay, Rizwan Afzal,
Sunil V. Rao MD The Duke Clinical Research Institute The Durham VA Medical Center Duke University Medical Center Transradial PCI in Octogenarians: Caveats,
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Gregg W. Stone, Tim Clayton, Roxana Mehran, Efthymios N. Deliargyris, Jayne Prats, Stuart J. Pocock TCT 2012; JACC 2012;60(17SupplB):B16 The HORIZONS-AMI.
Switch Switch Safety and Efficacy of Crossover (Switch) from UFH/Enox to Bivalirudin: Results from ACUITY Dr. Harvey White Green Lane Cardiovascular Service.
Use of Arteriotomy Closure Devices and the Risk of Vascular Complications: An Analysis of 227,879 Patients in the NCDR Sameer K. Mehta MD, Andrew D. Frutkin.
Athens Cardiology Update CADILLAC Study Blood Transfusion after Myocardial Infarction: Friend, Foe or double-edged Sword? Georgios I. Papaioannou,
Michael A. Nelson, MD 1 Michele D. Voeltz, MD 1 Frederick Feit, MD 2 A. Michael Lincoff, MD 3 Steven V. Manoukian, MD 1 1 Emory University School of Medicine.
Gregg W. Stone, Tim Clayton, Roxana Mehran, Efthymios N. Deliargyris, Jayne Prats, Stuart J. Pocock Bivalirudin Reduces Cardiac Mortality in Patients with.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Baseline Characteristics Current or Former Smoker Diabetic Hypertension 25.7 Prior MI Prior Heart Failure.
Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.
Are Benefits of Fondaparinux Maintained According to Various Procedural Strategies? Insights from OASIS 5 Martial Hamon, MD, FESC University Hospital of.
Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.
New Horizons for Patients with ST-Elevation Myocardial Infarction Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation.
TCT Presentation October 2006 Outcomes in Elderly Patients Undergoing PCI Treated with Bivalirudin Monotherapy versus Glycoprotein IIb/IIIa Inhibitors.
Is Bivalirudin Monotherapy Sufficient for Diabetic Patients with Acute Coronary Syndrome Undergoing PCI? Frederick Feit, Steven Manoukian, Ramin Ebrahimi,
Meta Analysis of Primary PCI trials Andreas Baumbach*, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran,
Dr Jonathan Day Senior Director Global Medical The Medicines Company Bivalirudin For patients with STEMI undergoing primary PCI.
ARNO TRIAL (Antithrombotic Regimens aNd Outcome) A RANDOMIZED TRIAL COMPARING BIVALIRUDIN WITH UNFRACTIONED HEPARIN IN PATIENTS UNDERGOING ELECTIVE PCI.
Major Bleeding is Associated with Increased 30-Day Mortality and Ischemic Complications in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing.
Dr Jonathan Day Senior Director Global Medical The Medicines Company Bivalirudin Advancing Anticoagulation in ACS.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Bivalirudin: Myths vs Reality? Dr Reman McDonagh Nycomed UK Ltd Conflict of Interest: Senior Manager working for Nycomed UK Ltd.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary.
Eptifibatide plus Heparin Increases the Risk of Major and Minor Hemorrhagic Complications Compared to Bivalirudin in Patients with Normal Renal Function.
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington,
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Impact Of Diabetes Mellitus On The Safety And Effectiveness Of Bivalirudin In Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty:
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Impact of Anticoagulation Regimens on Sheath Management and Bleeding in Patients Undergoing Elective Percutaneous Coronary Intervention in the STEEPLE.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.
Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven.
Heparin Should be the First-line Therapy for Patients with ACS/AMI
How To Minimize Bleeding In The Cath Lab
Impact of Radial Access on Bleeding
Major Bleeding is Associated with Increased Short-Term Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial.
Women, Bleeding, and Coronary Intervention
Why Radial Access Should be the Default for Women undergoing PCI?
Transfusion is Associated with Increased 30-Day Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial Steven.
Radial vs Femoral Access in ACS Patients
How to Minimize Bleeding in STEMI Patients Outline: -Know about bleeding -Think about consequences of bleeding -Identify bleeding risk factors -Maximize.
Dr. Harvey White on behalf of the ACUITY investigators
For the HORIZONS-AMI Investigators
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
% Heparin + GPI IIb/IIIa Bivalirudin +
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48
Outcomes in Elderly Patients Undergoing PCI Treated with Bivalirudin Monotherapy versus Glycoprotein IIb/IIIa Inhibitors with Heparin or LMWH: Results.
Implications of Preoperative Thienopyridine Use
on behalf of the ACUITY investigators
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Baseline Characteristics
The following slides are highlights of a report based on a TCTMD Webcast Scientific Presentation on February 19, 2003 that was originally presented by.
Presentation transcript:

1 Incidence, impact and preventative strategies for non- access site bleeding in the PCI patient Martial Hamon. MD. FESC University Hospital. Caen. France

Vascular Complications (%) P<0.001 For trend Doyle BJ et al. JACC Intervention 2008;1: Changing Incidence from the earliest (8.4%) to the contemporary time period (3.5%)

Doyle BJ et al. JACC Intervention 2008;1: Major Femoral Bleeding Complications After PCI Impact on Survival

Jolly S et al. Am Heart J 2009 Meta-analysis of 18 Randomized Trials Radial vs Femoral Access Impact on Major Bleeding RADIAL VS FEMORAL Favours RADIAL Favours FEMORAL Major Bleeding: 0.54% vs 2.32% (5 had no bleeding events) patients

Death,MI or Stroke Meta-analysis of Randomized Trials Radial vs Femoral Access Impact on Ischemic Outcomes Jolly S et al. Am Heart J 2009 RADIAL VS FEMORAL Favours RADIAL Favours FEMORAL Trend for reduction in composite of death.MI. stroke (2.5% vs 3.8%. P =.06)

Endpoint Measures at Day 30 Radial vs. Femoral 11.1%10.5%0.95 ( )0.62 Risk ratio ±95% CI Risk ratio ±95% CI Endpoint Net clinical outcome Ischemic composite Major bleeding Radial better Femoral better Radial (n=798) Femoral (n=11.988) OR (95% CI) adjusted p-value 7.4%8.1%1.10 ( ) %3.0%0.63 ( )0.02 ACUITY

7 ACUITY: Femoral vs. Radial Access Major or Minor Organ Bleeding Hamon M. Rasmussen LH. Manoukian SV. et al. EuroIntervention FemoralRadial Heparin+GPI Bivalirudin Major or minor organ bleeding were reduced to a similar extent in patients treated with bivalirudin alone compared to heparin plus a GPI and were present with both femoral access (4.1% vs 7.4% respectively. p<0.0001) and radial access (4.9% vs 7.2% respectively. p=0.26). 7.4% 4.1% 7.2%4.9%

ACUITY 30Days TRITON 3Days EARLY ACS 120hours SYNERGY 30Days OASIS 5 9days ABOARD 30Days Early Non-CABG Major Bleeding in ACS Trials in PCI-Treated Patients 88% Femoral Access 84% Radial Access Percent Protocol Major Bleed

9 Bleeding definitions Variation in definitions Intracranial hemorrhage Retroperitoneal hemorrhage Bleeding with 5g/dL fall in hemoglobin Bleeding with 3g/dL fall in hemoglobin 4g/dL fall in hemoglobin without site Blood transfusion  3 units TIMI Major TIMI Minor Gross hematuria or hematemesis Lincoff et al. JAMA 2003

Beyond Access Site Bleeding: Incidence, Sources, and Impact of Antithrombotic Therapy in the PCI Patient A Combined Analysis of 17,393 Patients REPLACE-2, ACUITY and HORIZONS-AMI Beyond Access Site Bleeding: Incidence, Sources, and Impact of Antithrombotic Therapy in the PCI Patient A Combined Analysis of 17,393 Patients REPLACE-2, ACUITY and HORIZONS-AMI Freek W.A. Verheugt, Steven R. Steinhubl, Martial Hamon, Harald Darius, Ph. Gabriel Steg, Marco Valgimigli, Steven P. Marso, Sunil V. Rao, Anthony H. Gershlick. Onze Lieve Vrouwe Gasthuis, Amsterdam

Bleeding Definitions - 30-day Endpoint 1.Protocol Major (different between REPLACE-2 and ACUITY, HORIZONS) 2.TIMI Major 3.TIMI Minor 4.TIMI Major + Minor 1.Protocol Major (different between REPLACE-2 and ACUITY, HORIZONS) 2.TIMI Major 3.TIMI Minor 4.TIMI Major + Minor

Purpose 1.To identify the incidence and source of bleeding events unrelated to access site among over 17,300 patients undergoing a PCI for a wide variety of clinical diagnoses. 2.Evaluate the impact of antithrombotic therapy (bivalirudin versus heparin + GPIIb/IIIa antagonist) on the occurrence of bleeding unrelated to the access site. 1.To identify the incidence and source of bleeding events unrelated to access site among over 17,300 patients undergoing a PCI for a wide variety of clinical diagnoses. 2.Evaluate the impact of antithrombotic therapy (bivalirudin versus heparin + GPIIb/IIIa antagonist) on the occurrence of bleeding unrelated to the access site.

Analysis Population: All PCI patients (ITT) from: REPLACE-2N = 6,002 ACUITYN = 7,789 HORIZONSN = 3,602 TotalN = 17,393* * For primary antithrombotic comparisons the GPIIb/IIIa antagonist + bivalirudin arm (n=2609) of ACUITY was excluded, leaving a total of 14,784 patients.

Patient Demographics – N=17,393 Age (years) Age ≥ 75 years (%) Weight (kg) Female (%) Diabetes (%) Current Smoker (%) CrCl < 60 Baseline Diagnosis STEMI NSTEMI Unstable Angina Stable Angina Other 62.3 ± % 85.6 ± % 25.1% 32.3% 17.0% 20.7% 30.0% 29.5% 8.6% 11.2%

Sources of Bleeding 1.Access Site Only 2.Both Access and Non-Access 3.Non-Access Site Only 4.No Identified Location 1.Access Site Only 2.Both Access and Non-Access 3.Non-Access Site Only 4.No Identified Location Location of bleeds were determined post hoc using investigator-identified location and without knowledge of randomized therapy. Intracranial Intraocular Gastrointestinal Genitourinary Pleural Pulmonary Head and Neck Epistaxis Hemoptysis Hematemasis Gingival Other

Sources and Incidence of TIMI Bleeding Among 17,393 PCI Patients 5.3% (n=925) of the study population experienced a TIMI (Major + Minor) bleeding event. Access-site only bleeds occurred in 357 (39.6%) of patients. Bleeding events not limited to the access site occurred in 568 (60.4%) of patients.

Figure 2 Incidence and Location of Bleeding Events Excluding Access Site

Adjusted Relative Risk of 1-Year Mortality Based on TIMI Bleeding Source Compared to No Bleeding P< for all bleeding versus none

Impact of Randomized Antithrombotic Therapy: All Bleeding Sources RR=0.52 P< RR=0.55 P< RR=0.55 P<0.0001

Relative RiskP-Value Access0.45< All Non-Access0.62< Both0.31< Non-Access Only No Location Bivalirudin betterHep + GPI better Figure 3 Impact of Randomized Antithrombotic Therapy on TIMI Major + Minor Bleeding by Source

Hep + GPI (%) Bivalirudin (%) Relative Risk Intracranial GI GU HEENT Pulmonary Other No Location All Non-Access Hep + GPI betterBivalirudin better Impact of Randomized Therapy on TIMI Bleeding by Location Exclusive of Access Site

Conclusions 1.Two-thirds of PCI patients with a TIMI bleed unrelated to the access site. 2.Bleeding, irrespective of the source, significantly associated with increased mortality at 1 year. 3.Non-access-related bleeding associated with double the risk of mortality compared to access bleeding. 4.The use of bivalirudin during a PCI associated with ~40% reduction in non-access site bleeding compared with heparin + a GPIIb/IIIa antagonist. 1.Two-thirds of PCI patients with a TIMI bleed unrelated to the access site. 2.Bleeding, irrespective of the source, significantly associated with increased mortality at 1 year. 3.Non-access-related bleeding associated with double the risk of mortality compared to access bleeding. 4.The use of bivalirudin during a PCI associated with ~40% reduction in non-access site bleeding compared with heparin + a GPIIb/IIIa antagonist.

23 Risk Factors For Bleeding in ACS Patients Patient relatedProcedural relatedTreatment related  Female gender  Older  Hypertension  Obesity  Low weight  Renal failure  Low platelet count. pre-existing aneamia  Medical history (GI disease)  Puncture site (femoral vs radial)  Level of puncture (femoral)  Larger arterial sheath  Prolonged sheath time  IABP placement  Concomitant venous sheath  Need for repeat intervention  Over anticoagulation  Type of anticoagulation (antiXa. direct thrombin inhibtor or LMWH and UFH)  GP IIb/IIIa inhibitors  Thrombolytic Reducing Bleeding Risk: Preventive Actions Patient levelProcedural levelTreatment level  Patient information (coughing. heavy lifting to be avoided after femoral puncture)  Nurse training for early recognition of retroperitoneal hemorrhage  Perfect puncture site  Angiographic control before closure device use  Alternative: RADIAL Access  Different access sites for staged procedures  Decrease size of arterial sheath  ACT during procedures for anticoagulation monitorring  Discontinuation of antithrombin after uncomplicated PCI  New Antithrombotic Agents (Bivalirudin. Fondaparinux) Identification of Risk Factors For Bleeding in ACS Patients and Preventive actions Hamon M. et al. EuroIntervention 2007 Identification Prevention

24 PCI in ACS: Choice of Access Site 1. Radial Access Feasible? 2. Consider Bleeding risk? Radial Access Consider bleeding risk Femoral Access Adjunctive therapy needed? YESNO 3. Consider Ischemic Risk? LOW HIGHLOW HIGH Default radial operators Am J Cardiol 2009 Hamon et al. BivalirudinBivalirudin or GPI